1.75
price up icon0.00%   0.00
after-market After Hours: 1.76 0.01 +0.57%
loading
Nkarta Inc stock is traded at $1.75, with a volume of 939.15K. It is up +0.00% in the last 24 hours and down -25.21% over the past month. Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
See More
Previous Close:
$1.75
Open:
$1.72
24h Volume:
939.15K
Relative Volume:
0.64
Market Cap:
$123.50M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.7292
EPS:
-2.4
Net Cash Flow:
$-114.31M
1W Performance:
-14.63%
1M Performance:
-25.21%
6M Performance:
-67.04%
1Y Performance:
-85.51%
1-Day Range:
Value
$1.695
$1.77
1-Week Range:
Value
$1.695
$2.05
52-Week Range:
Value
$1.695
$16.24

Nkarta Inc Stock (NKTX) Company Profile

Name
Name
Nkarta Inc
Name
Phone
(925) 407-1049
Name
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Name
Employee
159
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
NKTX's Discussions on Twitter

Compare NKTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NKTX
Nkarta Inc
1.75 123.50M 0 -117.50M -114.31M -2.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
479.79 123.21B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
698.74 76.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
624.67 37.96B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
246.75 31.94B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beone Medicines Ltd Adr
271.80 29.00B 3.32B -860.46M -1.04B -8.32

Nkarta Inc Stock (NKTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-09-24 Initiated Rodman & Renshaw Buy
Aug-14-24 Upgrade Raymond James Outperform → Strong Buy
Mar-22-24 Downgrade Raymond James Strong Buy → Outperform
Dec-22-22 Downgrade Oppenheimer Outperform → Perform
Oct-10-22 Initiated Canaccord Genuity Buy
Jul-28-22 Initiated Needham Buy
Jul-18-22 Initiated SVB Leerink Outperform
Mar-11-22 Initiated Raymond James Outperform
Mar-08-22 Initiated H.C. Wainwright Buy
Jan-06-22 Initiated William Blair Outperform
Nov-18-21 Initiated SMBC Nikko Outperform
Jul-16-21 Initiated Oppenheimer Outperform
Aug-04-20 Initiated Cowen Outperform
Aug-04-20 Initiated Evercore ISI Outperform
Aug-04-20 Initiated Mizuho Buy
Aug-04-20 Initiated Stifel Buy
View All

Nkarta Inc Stock (NKTX) Latest News

pulisher
01:24 AM

Comparing Tempest Therapeutics (NASDAQ:TPST) & Nkarta (NASDAQ:NKTX) - Defense World

01:24 AM
pulisher
Feb 25, 2025

Nkarta to Participate in March Investor Conferences - The Manila Times

Feb 25, 2025
pulisher
Feb 18, 2025

Leerink Partnrs Forecasts Nkarta FY2029 Earnings - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

Leerink Partnrs Comments on Nkarta FY2024 Earnings - Defense World

Feb 17, 2025
pulisher
Feb 16, 2025

Leerink Partnrs Comments on Nkarta FY2029 Earnings - Defense World

Feb 16, 2025
pulisher
Feb 15, 2025

Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Feb 15, 2025
pulisher
Feb 11, 2025

Stock Performance Spotlight: Nkarta Inc (NKTX) Ends the Day at 2.09, Down by -3.69 - The Dwinnex

Feb 11, 2025
pulisher
Feb 11, 2025

Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages - Defense World

Feb 11, 2025
pulisher
Feb 06, 2025

A new trading data show Nkarta Inc (NKTX) is showing positive returns. - SETE News

Feb 06, 2025
pulisher
Feb 06, 2025

Vasculitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, CytoDyn - The Globe and Mail

Feb 06, 2025
pulisher
Feb 05, 2025

Monitoring Nkarta Inc (NKTX) after recent insider movements - Knox Daily

Feb 05, 2025
pulisher
Feb 04, 2025

The Potential Rise in the Price of Trane Technologies plc (TT) following insiders activity - Knox Daily

Feb 04, 2025
pulisher
Feb 04, 2025

Closing Figures: Nkarta Inc (NKTX)’s Negative Finish at 2.17, Down -7.26 - The Dwinnex

Feb 04, 2025
pulisher
Jan 27, 2025

TANG CAPITAL MANAGEMENT LLC Increases Stake in Nkarta Inc - GuruFocus.com

Jan 27, 2025
pulisher
Jan 27, 2025

What Does Nkarta Inc’s (NASDAQ: NKTX) Future Hold? - Stocks Register

Jan 27, 2025
pulisher
Jan 21, 2025

Nkarta's chief medical officer sells $19,003 in stock - MSN

Jan 21, 2025
pulisher
Jan 21, 2025

Nkarta CEO Paul Hastings sells $38,231 in stock - MSN

Jan 21, 2025
pulisher
Jan 19, 2025

Nkarta executive sells shares worth $12,843 - MSN

Jan 19, 2025
pulisher
Jan 18, 2025

Nkarta's chief technical officer sells $16,383 in stock By Investing.com - Investing.com Australia

Jan 18, 2025
pulisher
Jan 18, 2025

Nkarta chief legal officer Alicia Hager sells $21,084 in stock - Investing.com India

Jan 18, 2025
pulisher
Jan 18, 2025

Nkarta chief legal officer Alicia Hager sells $21,084 in stock By Investing.com - Investing.com Australia

Jan 18, 2025
pulisher
Jan 18, 2025

Nkarta, Inc. (NASDAQ:NKTX) Insider Sells $19,003.60 in Stock - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

Nkarta, Inc. (NASDAQ:NKTX) CEO Sells $38,231.60 in Stock - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

JPMorgan Chase & Co. Purchases 761,349 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Jan 18, 2025
pulisher
Jan 18, 2025

Nkarta executive sells shares worth $12,843 By Investing.com - Investing.com South Africa

Jan 18, 2025
pulisher
Jan 17, 2025

Nkarta's chief medical officer sells $19,003 in stock By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 17, 2025

Nkarta's chief technical officer sells $16,383 in stock - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Consensus Target Price from Analysts - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of “Buy” by Brokerages - Defense World

Jan 17, 2025
pulisher
Jan 15, 2025

Nkarta, Inc. (NASDAQ:NKTX) Shares Acquired by Barclays PLC - Defense World

Jan 15, 2025
pulisher
Jan 12, 2025

Jane Street Group LLC Lowers Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Jan 12, 2025
pulisher
Jan 05, 2025

Geode Capital Management LLC Raises Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Jan 05, 2025
pulisher
Jan 03, 2025

Franklin Resources Inc. Takes Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Jan 03, 2025
pulisher
Jan 03, 2025

Analysts Think This Little-Known AI Stock Can Rally 50% in 2025. Is It Time to Buy? - The Globe and Mail

Jan 03, 2025

Nkarta Inc Stock (NKTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Nkarta Inc Stock (NKTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Levin Alyssa
See Remarks
Jan 15 '25
Sale
2.20
5,838
12,844
102,662
Brandenberger Ralph
Chief Technical Officer
Jan 15 '25
Sale
2.20
7,447
16,383
124,796
HASTINGS PAUL J
Chief Executive Officer
Jan 15 '25
Sale
2.20
17,378
38,232
319,859
Hager Alicia J.
Chief Legal Officer
Jan 15 '25
Sale
2.20
9,584
21,085
146,735
Hager Alicia J.
Chief Legal Officer
Jul 16 '24
Sale
8.00
3,396
27,168
103,819
Trager James
Chief Scientific Officer
Jun 18 '24
Sale
5.60
456
2,554
150,959
HASTINGS PAUL J
Chief Executive Officer
Jun 18 '24
Sale
5.60
1,770
9,912
240,737
Shook David
Chief Medical Officer
Jun 18 '24
Sale
5.60
456
2,554
116,524
Hager Alicia J.
Chief Legal Officer
Jun 18 '24
Sale
5.60
727
4,071
107,215
Brandenberger Ralph
Chief Technical Officer
Jun 18 '24
Sale
5.60
229
1,282
79,743
$22.68
price down icon 0.22%
$33.64
price up icon 0.81%
$81.55
price up icon 3.16%
$20.69
price up icon 11.90%
$112.92
price up icon 3.79%
biotechnology ONC
$271.80
price down icon 2.36%
Cap:     |  Volume (24h):